Virtu Financial’s ARS Pharmaceuticals SPRY Stock Holding History

Virtu Financial’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$88K	Buy	+10,938	New	+$94.1K	﹤0.01%	1133
2024 Q2	–	Sell	-20,201	Closed	-$206K	–	1849
2024 Q1	$206K	Buy	+20,201	New	+$151K	0.02%	776
2023 Q4	–	Sell	-80,816	Closed	-$305K	–	1973
2023 Q3	$305K	Buy	+80,816	New	+$530K	0.03%	500
2023 Q2	–	Sell	-10,411	Closed	-$68K	–	2003
2023 Q1	$68K	Buy	+10,411	New	+$80K	0.01%	1051
2022 Q1	–	Sell	-20,317	Closed	-$135K	–	2002
2021 Q4	$135K	Buy	+20,317	New	+$165K	0.01%	998

Other funds holding SPRY

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Virtu Financial's SPRY Position: Q2 2026 in Review

Virtu Financial opened a new position in ARS Pharmaceuticals (SPRY) in Q2 2026: 10,938 shares worth $88K. The stake represents ﹤0.01% of the portfolio and ranks #1133 among its holdings. This is a return to the name: Virtu Financial previously reported a position in SPRY as recently as Q1 2024.

Virtu Financial first reported a position in SPRY in Q4 2021 and has held it in 5 quarters since. The position peaked at $305K in Q3 2023. 209 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

Virtu Financial held 10,938 shares of ARS Pharmaceuticals worth $88K as of Q2 2026.
ARS Pharmaceuticals was a new Virtu Financial position in Q2 2026.
ARS Pharmaceuticals made up ﹤0.01% of Virtu Financial's portfolio in Q2 2026, its #1133 holding.
Virtu Financial first reported a position in ARS Pharmaceuticals in Q4 2021 and has held it in 5 quarters since.
Virtu Financial's ARS Pharmaceuticals position peaked at $305K in Q3 2023.
209 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.